Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 34Terminated 14Unknown 3Active not recruiting 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Anemia, Refractory, with Excess of Blasts 2Recurrence 1Non-Malignant Neoplasm 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 29fludarabine 19Rituximab 15fludarabine phosphate 12Specimen Handling 8obinutuzumab 7Immunotherapy, Adoptive 7Lenalidomide 6Etoposide 6pirtobrutinib 5ibrutinib 5glofitamab 5axicabtagene ciloleucel 5Whole-Body Irradiation 5Mycophenolic Acid 5venetoclax 4polatuzumab vedotin 4Prednisone 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Blood Component Removal 4Biopsy 4pembrolizumab 3daratumumab 3X-Rays 3Vincristine 3Stem Cell Transplantation 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Non-Hodgkin × Antilymphocyte Serum × Clear all
NCT02727803 2026-05-22

Personalized NK Cell Therapy in CBT

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡